89Zr-DFO-Nimotuzumab

N/A

Report date: 2025/09/12 20:01:19

NME

Base Information

Drug Name89Zr-DFO-Nimotuzumab

Drug Alias Name锆[89Zr]-DFO-尼妥珠单抗

ClassificationRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsLung NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Saskatchewan

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Saskatchewan

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A